Description

Y-shape PEG NHS Ester with superior quality specification of ≥95% Substitution.

Y-shape PEG NHS from JenKem Technology is a Succinimidyl Carboxymethyl Ester branched 2ARM PEG, reactive towards the amino group of lysine(s) on proteins or other biologics. Amine PEGylation with Y-shape PEG NHS can be completed in less than 1hr at pH 7-8. JenKem proprietary Y-shape PEGs are more selective, due to their sterically bulky structure. Please review the application note for this product for additional instructions for amine PEGylation with Y-NHS-40K.

JenKem Technology offers Y-shape PEG NHS with MW 40000, in 1g and 10g packing sizes.  JenKem Technology provides repackaging services for an additional fee, please contact us if you require a different package size than our catalog selection.

Different MW of Y-shape PEG NHS products may be available by custom synthesis, please email us at tech@jenkemusa.com for details on custom PEGs.

Bulk PEGs and GMP grade PEGs are made-to-order. Please contact us for bulk pricing.

Application of Y-NHS-40K for PEGylation:

Drug Molecule or Other Entity PEGylated with Y-NHS-40K	References
Calcium phosphate nanoparticles	7
Cp40	4
DNA aptamer (SOMAmer)	2
G-CSF	15
Gentamicin	14
IFN-α2a	16
IFN-α2b	17
LIF receptor antagonist (LA)	11
L-RNA (Spiegelmer)	5
L-RNA (Spiegelmer)	8
rhGH	18
TNF-α	9, 10

Click here to download the MSDS

References:

1. AlQahtani, A.D., et al., Production of “biobetter” glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment, European Journal of Pharmaceutical Sciences, 2019, 127, P. 79-91.

2. Haruta, K., et al., A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers, Nucleic acid therapeutics, 2017, 27(1):36-44.

3. Guo, L., et al., Application Instructions for Y-NHS-40K for Amine PEGylation, click link.

4. Masao, H., et al., Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys, Nucleic Acid Therapeutics, 2015.

5. Winship, A.L., Interleukin-11 alters placentation and causes preeclampsia features in mice, Proc Natl Acad Sci U S A., 2015, 112(52):15928-33.

6. Risitano, A.M., et al., Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria, Blood Mar, 2014, 123 (13) 2094-2101.

7. Roccaro, Aldo M. et al., SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy, Cell Reports, 2014, 9 (1), p: 118 – 128.

8. Stefan, N., et al., Novel Prodrug-Like Fusion Toxin with Protease-Sensitive Bioorthogonal PEGylation for Tumor Targeting, Bioconjugate chemistry, 2014, 25.12: 2144-2156.

9. Ashokan, A., et al., Multifunctional calcium phosphate nano-contrast agent for combined nuclear, magnetic and near-infrared in vivo imaging. Biomaterials, 2013, 34(29): p. 7143-7157.

10. Khan, M.A., et al., Targeting complement component 5a promotes vascular integrity and limits airway remodeling, PNAS, 2013, 110(15) p:6061-6066.

11. Dai, C.Y., et al., Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application, Science China Life Sciences, 2013, 56.1 : 51-58.

12. Dai, C.Y., et al., Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma, Science China Life Sci, 2011, 54(2): 128–138.

13. Menkhorst, E., et al., Vaginally Administered PEGylated LIF Antagonist Blocked Embryo Implantation and Eliminated NonTarget Effects on Bone in Mice, PLoS ONE, 2011, 6 (5) e19665.

14. Cai, Y., et al., Separation of exenatide analogue mono-PEGylated with 40 kDA polyethylene glycol by cation exchange chromatography, Journal of Chromatography A, 2011, 1218:39, P. 6953-6960.

15. Wang, Y-J., et al., PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin, Journal of Controlled Release, 2010, 145:3, p. 306-313.

16. Marcus, Y., et al., Turning Low-Molecular-Weight Drugs into Prolonged Acting Prodrugs by Reversible Pegylation: A Study with Gentamicin, Journal of Medicinal Chemistry, 2008, 51 (14), 4300-4305.

17. Wang, S., et al., Y-type polyethylene glycol modified G-CSF and preparation method and use thereof. Patent CN200780051378, 2007.

18. Zhou, W., et al., Interferon alpha 2a modified by polyethylene glycol, its synthesis process and application. Patent CN200780050541, 2007.

19. Zhou, W., et al., Interferon alpha 2b modified by polyethylene glycol, its synthesis process and application. Patent CN200780050542, 2007.

20. Zhou, W., et al., Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof. Patent CN200880009718, 2008.

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7A guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.

enKem Technology利用数十年来在创新PEG和单分散PEG衍生物，PEG共聚物和PEG化共轭物的研究，开发和制造方面的专业知识，提供定制PEG合成服务。JenKem Technology已为许多PEG相关技术申请了专利，并尊重他人的知识产权。2020年7月，JenKem Technology获得67项专利批准（中国35项，美国20项，欧洲8项，日本3项，澳大利亚1项），48项待批专利申请（中国22项，美国16项，欧洲5项，1项）印度，巴西1，韩国1、2 PCT），向FDA提交的几种DMF以及正在开发的许多其他创新技术。我们将聘请我们经验丰富的专业技术支持专家来帮助您为您的项目确定正确的高质量PEG。JenKem Technology的研发团队将开发和合成您的PEG或PEG共聚物产品，以在最短的时间内以最高的质量满足您项目的独特需求。通过专用的PEG化服务提供  定制的PEG化缀合物。JenKem Technology还通过定制合成来制造GMP级PEG衍生物和批量订单，从而提供了满足客户特殊质量要求的机会。根据ICH Q7A准则，JenKem Technology能够根据ISO 9001和ISO 13485认证的质量管理体系开发和合成多种GMP PEG衍生物。JenKem Technology可以帮助客户向美国FDA提交DMF，并具有在全球范围内申请专利以保护客户利益的能力。有关JenKem Technology的定制PEG合成服务的详细信息，请通过tech@jenkemusa.com与我们联系。有关我们当前的PEG产品目录的信息，请访问  左侧的PEG产品页面。对于可能有现货的定制产品，请定期访问此链接。JenKem Technology由PEG合成和PEG化的专家成立于2001年，专门研究和生产高质量聚乙二醇（PEG）产品和衍生物，以及相关的定制合成和PEG化服务。JenKem Technology已通过ISO 9001和ISO 13485认证，并遵守ICH Q7A GMP制造准则。JenKem®PEG的生产已从环氧乙烷反向整合到内部聚合中，从而为受监管的客户提供了简便的可追溯性。从实验室规模到大型商业规模，JenKem Technology均可满足制药，生物技术，医疗设备和诊断程序以及新兴化学专业市场的聚乙二醇化需求。